CHANDLER, Ariz., Feb. 22, 2012 /PRNewswire/ -- Vomaris Innovations, Inc., a leading regenerative medicine company focusing on wound care with bioelectric technology, has named Michael P. Nagel as its new President and Chief Executive Officer. Mr. Nagel will also join Vomaris Innovations, Inc.'s Board of Directors. Mr. Nagel brings more than 26 years of sales, marketing and management experience in the medical device industry along with a visionary leadership approach. Before joining Vomaris, Nagel served as Chief Commercial Officer of Neomend. He has also served as Vice President of Sales and Marketing at Incisive Surgical and was co-founder and Vice President of Sales and Marketing at Vascular Solutions (VASC).
At Neomend, Nagel oversaw the commercial launch of a PMA device, Progel®, a pleural air leak sealant that quickly penetrated more than 1,200 hospitals and experienced rapid sales growth in the United States and Europe. He helped take Vascular Solutions from inception to IPO in 39 months and led the launch of a novel, biological vascular closure device into the interventional marketplace. With Incisive Surgical, Nagel led the launch of a new, absorbable skin closure technology, INSORB, built the entire distribution channel, sold INSORB to more than 1,000 U.S. hospitals and then launched the technology in Europe.
"With expertise ranging from diagnostics to cardiovascular devices, Nagel's proven leadership skills in commercializing biological sealants, hemostats and biomaterials will drive the regenerative technology at Vomaris forward," said Paul Foster, Chairman of Vomaris. "Mike brings the proven experience and leadership needed to accelerate the continued development and commercial launch of an innovative wound care technology. In addition, he brings unparalleled expertise in launching new technology into the medical marketplace that will help Vomaris expand its reach and become a global company," continued Foster.
"I value the opportunity to work with an elite, highly focused team including employees and leading physicians who are dedicated to redefining wound care advancements," Nagel said. "Driven by the increasing number of patients suffering from full-thickness wounds, there is a need to provide an advanced technology that will help expedite wound healing while reducing the associated pain and scarring. Vomaris is changing how wounds are managed, which will enhance the quality of patient care worldwide," continued Nagel.
The Company's product Procellera® is the first totally self-contained, comfortable, cut-to-fit, electrically active wound dressing in the world. The technology is extremely versatile and scalable and spans multiple healthcare specialties. For more information about Procellera®, please visit www.vomaris.com.
About Vomaris Innovations, Inc.
Vomaris Innovations, Inc., based in Chandler, Arizona, is a regenerative medical device company specializing in the emerging bioelectrical field, generating innovative technologies for the wound care market. FDA cleared, Procellera® Wound Dressing is the world's first wireless, self-contained antimicrobial wound dressing that generates a sustained electrical microcurrent at its surface when activated with a conductive fluid. Procellera® is indicated for professional use for partial and full-thickness wounds such as pressure ulcers, venous ulcers, diabetic ulcers, burns, surgical incisions, and donor/recipient graft sites. Randomized controlled trials are in process to obtain clinical data for supporting expanded indications for use, including faster healing, reduced pain and decreased scarring. A recently published study in the Journal of Burn Care and Research on skin graft donor site wounds concluded that Procellera® healed wounds 35% faster and resulted in a significant decrease in scar appearance and improved patient subjective outcomes as compared to semi-occlusive control wound dressings. Vomaris' ongoing research efforts are focused on evaluating additional benefits associated with emerging bioelectrical field generating technologies. For more information, visit www.vomaris.com or call 480.921.4948.
SOURCE Vomaris Innovations, Inc.
Advertisement
At Neomend, Nagel oversaw the commercial launch of a PMA device, Progel®, a pleural air leak sealant that quickly penetrated more than 1,200 hospitals and experienced rapid sales growth in the United States and Europe. He helped take Vascular Solutions from inception to IPO in 39 months and led the launch of a novel, biological vascular closure device into the interventional marketplace. With Incisive Surgical, Nagel led the launch of a new, absorbable skin closure technology, INSORB, built the entire distribution channel, sold INSORB to more than 1,000 U.S. hospitals and then launched the technology in Europe.
Advertisement
"With expertise ranging from diagnostics to cardiovascular devices, Nagel's proven leadership skills in commercializing biological sealants, hemostats and biomaterials will drive the regenerative technology at Vomaris forward," said Paul Foster, Chairman of Vomaris. "Mike brings the proven experience and leadership needed to accelerate the continued development and commercial launch of an innovative wound care technology. In addition, he brings unparalleled expertise in launching new technology into the medical marketplace that will help Vomaris expand its reach and become a global company," continued Foster.
"I value the opportunity to work with an elite, highly focused team including employees and leading physicians who are dedicated to redefining wound care advancements," Nagel said. "Driven by the increasing number of patients suffering from full-thickness wounds, there is a need to provide an advanced technology that will help expedite wound healing while reducing the associated pain and scarring. Vomaris is changing how wounds are managed, which will enhance the quality of patient care worldwide," continued Nagel.
The Company's product Procellera® is the first totally self-contained, comfortable, cut-to-fit, electrically active wound dressing in the world. The technology is extremely versatile and scalable and spans multiple healthcare specialties. For more information about Procellera®, please visit www.vomaris.com.
About Vomaris Innovations, Inc.
Vomaris Innovations, Inc., based in Chandler, Arizona, is a regenerative medical device company specializing in the emerging bioelectrical field, generating innovative technologies for the wound care market. FDA cleared, Procellera® Wound Dressing is the world's first wireless, self-contained antimicrobial wound dressing that generates a sustained electrical microcurrent at its surface when activated with a conductive fluid. Procellera® is indicated for professional use for partial and full-thickness wounds such as pressure ulcers, venous ulcers, diabetic ulcers, burns, surgical incisions, and donor/recipient graft sites. Randomized controlled trials are in process to obtain clinical data for supporting expanded indications for use, including faster healing, reduced pain and decreased scarring. A recently published study in the Journal of Burn Care and Research on skin graft donor site wounds concluded that Procellera® healed wounds 35% faster and resulted in a significant decrease in scar appearance and improved patient subjective outcomes as compared to semi-occlusive control wound dressings. Vomaris' ongoing research efforts are focused on evaluating additional benefits associated with emerging bioelectrical field generating technologies. For more information, visit www.vomaris.com or call 480.921.4948.
SOURCE Vomaris Innovations, Inc.
